

7. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol*. 1999;17(12):3835-3849.
8. Percy C, Fritz A, Jack A, et al. *International Classification of Diseases for Oncology (ICD-O-3)*. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
9. World Health Organization. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. 4th ed. Lyon, France: IARC Press; 2008.
10. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol*. 2008;26(25):4124-4130.
11. Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. *Br J Haematol*. 2008;140(5):516-526.
12. Geissinger E, Odenwald T, Lee SS, et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells. *Virchows Arch*. 2004;445(4):334-343.
13. Charton-Bain MC, Brousset P, Bouabdallah R, et al. Variation in the histological pattern of nodal involvement by gamma/delta T-cell lymphoma. *Histopathology*. 2000;36(3):233-239.
14. Gaulard P, Belhadj K, Reyes F. Gammadelta T-cell lymphomas. *Semin Hematol*. 2003;40(3):233-243.
15. Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK. Enteropathy-type T-cell lymphoma. *Am J Clin Pathol*. 2007;127(5):701-706.
16. Zettl A, Ott G, Makutik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. *Am J Pathol*. 2002;161(5):1635-1645.
17. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. *Blood*. 2009;113(17):3931-3937.
18. Shapira MY, Caspi O, Amir G, Zlotogorski A, Naparstek Y. Gastric-mucocutaneous gammadelta T cell lymphoma: possible association with Epstein-Barr virus? *Leuk Lymphoma*. 1999;35(3):397-401.
19. Kanavaros P, Boulland ML, Pettit B, Amuff B, Gaulard P. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression. *Leuk Lymphoma*. 2000;38(3):317-326.
20. Kinney MC. The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms. *Am J Clin Pathol*. 1999;111(1 suppl 1):S104-S118.
21. Toro JR, Liewehr DJ, Pabby N, et al. Gammadelta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. *Blood*. 2003;101(9):3407-3412.
22. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood*. 2006;107(1):265-276.
23. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood*. 2008;111(12):5496-5504.
24. Verbeek WH, von Blomberg BM, Scholten PE, et al. The presence of small intestinal intraepithe-
- lial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease. *Am J Gastroenterol*. 2008;103(12):3152-3158.
25. Posner LE, Robert-Guroff M, Kalyanaraman VS, et al. Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. *J Exp Med*. 1981;154(2):333-346.
26. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. *Proc Natl Acad Sci U S A*. 1982;79(6):2031-2035.
27. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. *Am J Surg Pathol*. 2007;31(7):1077-1088.
28. de Leval L, Gaulard P. Pathobiology and molecular profiling of peripheral T-cell lymphomas. *Hematology Am Soc Hematol Educ Program*. 2008;2008:272-279.
29. Rodriguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T-cell lymphoma with follicular T-cell markers. *Am J Surg Pathol*. 2008;32(12):1787-1799.
30. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. *Am J Surg Pathol*. 2006;30(4):490-494.
31. Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. *Br J Haematol*. 2007;137(5):416-422.
32. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. *Hematology Am Soc Hematol Educ Program*. 2001;2001:259-281.
33. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-natural killer cell lymphoproliferative diseases. *Semin Hematol*. 2003;40(2):124-132.
34. Wang B, Yao K, Liu G, et al. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. *Cell Mol Immunol*. 2009;6(2):97-103.
35. Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. *Ann Oncol*. 2009;20(4):715-721.
36. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood*. 2004;103(7):2474-2479.
37. Pescarmona E, Pignolon P, Puopolo M, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. *J Pathol*. 2001;195(3):361-366.
38. Rassidakis GZ, Jones D, Lai R, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. *J Pathol*. 2003;200(2):240-248.
39. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol*. 2002;13(1):140-149.
40. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. *Blood*. 2006;108(13):4163-4169.
41. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. *Am J Surg Pathol*. 2005;29(10):1284-1293.
42. Chtanova T, Kemp RA, Sutthelund AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. *J Immunol*. 2001;167(6):3057-3063.
43. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. *Immunity*. 2001;15(3):375-385.
44. McHugh RS, Whitters MJ, Piccinillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. *Immunity*. 2002;16(2):311-323.
45. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. *J Exp Med*. 2004;199(11):1479-1489.
46. Kim CH, Lim HW, Kim JR, et al. Unique gene expression program of human germinal center T helper cells. *Blood*. 2004;104(7):1952-1960.
47. Fortenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity*. 2005;22(3):329-341.
48. Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. *Clin Cancer Res*. 2004;10(15):4971-4982.
49. Martinez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. *Leukemia*. 2005;19(12):2254-2263.
50. Piccaluga PP, Agostinelli C, Zinzani PL, et al. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. *Lancet Oncol*. 2005;6(6):440.
51. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. *Oncogene*. 2006;25(10):1560-1570.
52. de Leval L, Rickman DS, Thielens C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. *Blood*. 2007;109(11):4952-4963.
53. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. *Blood*. 2007;109(5):2156-2164.
54. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. *Cancer Res*. 2007;67(22):10703-10710.
55. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. *J Clin Invest*. 2007;117(3):823-834.
56. Rodriguez-Antona C, Leskela S, Zajac M, et al. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. *Blood*. 2007;110(9):3345-3351.
57. Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. *J Clin Oncol*. 2007;25(22):3321-3329.
58. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. *Blood*. 2010;115(5):1026-1036.
59. Huang Y, de Reynies A, de Leval L, et al. Gene

- expression profiling identifies emerging oncogenic pathways operating in extranodal NK-/T-cell lymphoma, nasal type. *Blood*. 2010;115(6):1226-1237.
60. Nelson M, Horsman DE, Weisenburger DD, et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. *Br J Haematol*. 2008;141(4):461-469.
 61. Leich E, Haralambieva E, Zettl A, et al. Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. *J Pathol*. 2007;213(1):99-105.
 62. Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. *Leukemia*. 2008;22(6):1139-1143.
 63. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. *Am J Pathol*. 2004;164(5):1837-1848.
 64. Metzker ML. Sequencing technologies: the next generation. *Nat Rev Genet*. 2010;11(1):31-46.
 65. Abouyabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstract]. *Blood*. 2007;110(11):Abstract 3452.
 66. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. *J Clin Oncol*. 2002;20(10):2472-2479.
 67. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. *Blood*. 2004;104(3):626-633.
 68. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood*. 2004;104(3):634-641.
 69. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. *Leukemia*. 2006;20(9):1533-1538.
 70. Shapiro M, Wasik MA, Junkins-Hopkins JM, et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. *Am J Hematol*. 2003;74(1):46-51.
 71. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. *Blood*. 2003;102(13):4284-4289.
 72. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. *Blood*. 2004;103(8):2920-2924.
 73. Janik JE, Dunleavy K, Pittaluga S, et al. A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies [abstract]. *Blood*. 2005;106(11):Abstract 3348.
 74. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. *Blood*. 2007;110(7):2316-2323.
 75. Kim JS, Kim S-J, Lee HW, et al. A pilot study of alemtuzumab plus combination chemotherapy for newly diagnosed patients with peripheral T-cell lymphomas [abstract]. *Blood*. 2006;108(11):Abstract 4717.
 76. Intragumtornchai T, Bunworasate U, Nakom TN, Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma [abstract]. *Blood*. 2006;108(11):Abstract 4740.
 77. Forero-Torres A, Bernstein SH, Gopal A, et al. SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) [abstract]. *Blood*. 2006;108(11):Abstract 2718.
 78. Ansell SM, Horwitz SM, Engert A, et al. Phase III study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *J Clin Oncol*. 2007;25(19):2764-2769.
 79. Borchmann P, Trenl JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. *Blood*. 2003;102(10):3737-3742.
 80. Heuck F, Ellemann J, Borchmann P, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. *J Immunother*. 2004;27(5):347-353.
 81. Cerveny CG, Law C-L, McCormick RS, et al. The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkin disease growth and sensitizes cells to established chemotherapeutics [abstract]. *Blood*. 2004;104(11):Abstract 2639.
 82. Shustov AR, Advani R, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. *Blood*. 2010;116(21):Abstract 961.
 83. O'Mahony D, Morris JC, Moses L, et al. Phase I trial of sipiluzumab in CD2-positive lymphoproliferative disease [abstract]. *Blood*. 2005;106(11):Abstract 3353.
 84. Casale DA, Bartlett NL, Hurd DD, et al. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia [abstract]. *Blood*. 2006;108(11):Abstract 2727.
 85. O'Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with sipiluzumab, a novel anti-CD2 mediated T- and NK-cell depleting agent, in patients with T-cell malignancies [abstract]. *Blood*. 2007;110(11):Abstract 3565.
 86. d'Amore F, Radford J, Jerkeman M, et al. Zanidamab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma [abstract]. *Blood*. 2007;110(11):Abstract 3409.
 87. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. *Leukemia*. 2005;19(11):1993-1995.
 88. Advani R, Hong F, Ganjoo KN, et al. Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 Trial [abstract]. *Blood*. 2009;114(22):Abstract 1671.
 89. Dang NH, Pro B, Hagemester FB, et al. Phase II trial of denileukin difitox for relapsed/refractory T-cell non-Hodgkin lymphoma. *Br J Haematol*. 2007;136(3):439-447.
 90. Foss F, Sjak-Shie N, Goy A, et al. Denileukin difitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL): the CONCEPT trial [abstract]. *Blood*. 2007;110(11):Abstract 3449.
 91. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. *J Clin Oncol*. 2000;18(6):1622-1636.
 92. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol*. 2007;25(21):3109-3115.
 93. Bates S, Piekarz R, Wright J, et al. Final clinical results of a phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included) [abstract]. *Blood*. 2008;112(11):Abstract 1568.
 94. Gloucester Pharmaceuticals Inc. Romidepsin: Sponsor's background package for the Oncologic Drugs Advisory Committee Meeting, September 2, 2009. <http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180633.pdf>. Accessed February 8, 2010.
 95. Piekarz R, Wright J, Fyfe R, et al. Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) [abstract]. *Blood*. 2009;114(22):Abstract 1657.
 96. Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. *Blood*. 2009;114(22):Abstract 920.
 97. Wang ES, O'Connor O, She Y, et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. *Leuk Lymphoma*. 2003;44(6):1027-1035.
 98. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. *J Clin Oncol*. 2009;27(26):4357-4364.
 99. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol*. 2011;29(9):1182-1189.
 100. Crabtree GR. Calcium, calcineurin, and the control of transcription. *J Biol Chem*. 2001;276(4):2313-2316.
 101. Advani R, Horwitz S, Zelenetz A, Horing SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. *Leuk Lymphoma*. 2007;48(3):521-525.
 102. Joly B, Frenkel V, Gaulard P, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL): preliminary results in 9 patients treated in a single institution [abstract]. *Blood*. 2005;106:Abstract 2686.
 103. Dueck GS, Chua N, Prasad A, et al. Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases [abstract]. *J Clin Oncol*. 2009;27:439s.
 104. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. *J Clin Oncol*. 2000;18(13):2603-2606.
 105. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. *Cancer*. 2005;104(11):2437-2441.
 106. Rupoli S, Goteri G, Picardi P, et al. Alemtuzumab in combination with interferon- α or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results [abstract]. *Blood*. 2008;112(11):Abstract 5000.
 107. Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL) [abstract]. *Blood*. 2008;112(11):Abstract 2005.
 108. Dhillon N, Bakkanagari S, Ng C, et al. Cutaneous T cell lymphoma: responses in phase 1 trial

- of combination therapy with liposomal doxorubicin, bortezomib, and gemtastabine [abstract]. *Blood*. 2006;108(11):Abstract 2466.
109. Duvic M, Forero-Torres A, Foss F, Olsen EA, Kim Y. Oral forodesine (BCS-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study [abstract]. *Blood*. 2006;108(11):Abstract 2467.
 110. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. *J Clin Oncol*. 2007;25(27):4293-4297.
 111. Delmer A, Fitoussi O, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [ASCO abstract 8554]. *J Clin Oncol*. 2009;27:447s.
 112. Marchi E, Paoluzzi L, Venkatraman SE, O'Connor OA. Pralatrexate (PDX) complements the activity of the proteasome inhibitor bortezomib (B) in *in vitro* models of lymphoid T-cell malignancies [abstract]. *Blood*. 2008;112(11):Abstract 3619.
 113. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. *J Invest Dermatol*. 2006;126(7):1641-1647.
 114. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. *J Clin Oncol*. 2009;27(33):5594-5600.
 115. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. *Int J Hematol*. 2003;78(2):163-167.
 116. Yamaguchi M, Kwong Y, Maeda Y, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK-/T-cell lymphoma, nasal type: NKTSG study [ASCO abstract 8044]. *J Clin Oncol*. 2010;28(suppl):15.
 117. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. *J Clin Oncol*. 2007;25(34):5458-5464.
 118. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. *N Engl J Med*. 1995;332(26):1744-1748.
 119. Bazarbachi A, Plumelle Y, Carlos RJ, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. *J Clin Oncol*. 2010;28(27):4177-4183.
 120. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. *J Clin Oncol*. 2010;28(9):1591-1598.
 121. Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *J Clin Oncol*. 2008;26(14):2264-2271.
 122. d'Amore F, Relander T, Lauritzen G, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL): a phase II study of the Nordic Lymphoma Group (NLG) [abstract]. *Blood*. 2006;108(11):Abstract 401.
 123. Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. *Bone Marrow Transplant*. 2004;33(4):405-410.
 124. Smith SD, Bolwell BJ, Rybicki LA, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. *Bone Marrow Transplant*. 2007;40(3):239-243.
 125. Chen AI, McMillan A, Negrin RS, Horing SJ, Laport GG. Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: the Stanford experience [abstract]. *Blood*. 2007;110(11):Abstract 1906.
 126. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. *J Clin Oncol*. 2009;27(1):106-113.
 127. Lansigan F, Seropian S, Cooper D, Foss F. A retrospective comparison of autologous vs. allogeneic transplantation for peripheral T-cell lymphoma: a single institution experience [abstract]. *Blood*. 2008;112(11):Abstract 4392.
 128. Sieniawski M, Lennard J, Millar C, et al. Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens [abstract]. *Blood*. 2009;114(22):Abstract 1660.

